ArticleJournal of translational medicine2026
METTL13 mediated SAA1 translation maintains cancer stem cell behavior and promotes esophageal carcinoma progression.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethyltransferase 13 (METTL13) is a methyltransferase involved in mRNA translation and could function as either oncogene or tumor suppressor in cancers, but its function and mechanism in esophageal cancer remain unknown. In this study, we revealed that METTL13 promotes esophageal squamous cell carcinoma (ESCC) progression through methylation-dependent mRNA translation.
methodsMETTL13 expression was analyzed using clinical database The Cancer Genome Atlas (TCGA) and ESCC samples collected. In vitro assays including CCK-8, colony formation, transwell and sphere-forming were utilized to determine the oncogenic functions of METTL13. Polyribosome-bound mRNA sequencing was performed to evaluate mRNA translation efficiencies under regulation of METTL13, which were further confirmed by quantitative RT-PCR and western blot. Alterations of Oxygen Consumption Rate (OCR) and levels of metabolites involved in lipid metabolism by seahorse assay and specific kits were detected respectively in ESCCs under METTL13 knockdown. ESCC mouse models were established to evaluate the oncogenic functions of METTL13 in vivo.
resultsMETTL13 is significantly up-regulated in clinical ESCC tissues and its high expression is associated with poor patient prognosis. Gain-of-function and loss-of-function assays demonstrated the critical function of METTL13 in regulation of ESCC progression in vitro and in vivo. Further mechanistic exploration has shown that METTL13 regulates ESCC by mediating the expression of Serum amyloid A1 (SAA1) at the translation level, which leads to lipid metabolism alteration. Sphere-forming assay experiments demonstrated that METTL13 plays an essential role in CSC-like properties in ESCC.
conclusionMETTL13 plays the essential oncogenic role in ESCC by enhancing SAA1 expression at translational level, leading to aberrant lipid metabolism. Our study provides the molecular basis for development of effective therapeutic strategies for ESCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.